Bio3 Research s.r.l. is a private
biopharmaceutical company based in Milan, Italy, with a USA
subsidiary,Bio3 Research Inc. based in Hayward/CA.
Bio3 Research develops new proprietary compounds up to Phase I/Phase IIA stage in:
cardiovascular field
tissue regeneration
nephrology
Development activity is ongoing in the area of
cardiovascular disorders related to HMGB1 (High Mobility Group Box 1)
over-expression.
Preclinical studies have shown that the HMGB1 protein as
such and its fragments have potential in Connective Tissue Regeneration
(wound healing, cartilage repair, bone matrix regeneration, burns, bedsores
etc).
Nephrology is another Bio3 Research field of interest.
Bio3 Research collaborates with biopharmaceutical companies, Academies,
individual scientists, to identify commercially promising innovations to patent
and develop them for commercial fruition in the pharmaceutical
marketplace.
Bio3 News...
Bio3 Research has recently been granted from USPTO the
US
patent # 10/471,641 which claims the use of HMGB1 inhibitors and antagonists for
the treatment of Cardiovascular Disorders…
